Genetic Alteration Profiling in North Macedonian Lung Cancer Patients

Eftimov, Aleksandar; Jovanovikj, Rubens; Kostadinova Kunovska, Slavica; Bogdanovska Todorovska, Magdalena; Ilievski, Boro; Zdravkovski, Panche; Komina, Selim; Krstevska, Blagica; Crvenkova, Simonida; Simonovska, Marija; Petrushevska, Gordana

doi:10.3390/genes16101177

Genetic Alteration Profiling in North Macedonian Lung Cancer Patients

Journal

Genes

Date Issued

2025-10-10

Author(s)

Simonovska, Marija

DOI

10.3390/genes16101177

Abstract

Background/Objectives: Late diagnosis and inefficient treatment regimens lead to poor prognosis, with a low 5-year survival rate for both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). New targeted therapeutic agents can be developed and introduced only by first discovering new driver oncogenes and with a thorough investigation of the known driver genes. The aim of the current study is to investigate the prevalence of alterations in the eight most frequently altered genes in lung cancer-BRAF, EGFR, KRAS, ALK, ROS1, HER2, PD-L1 and PIK3CA. Methods: Real-time polymerase chain reaction (RT-PCR) was used to detect KRAS and EGFR mutations, multiplex PCR and microarray hybridization for KRAS/BRAF/PIK3CA mutations. Immunohistochemical analysis was performed for the detection of ALK, HER2/NEU, ROS-1 and PD-L1 alterations. Results: Overall, 221/603 patients (36.65%) had at least one genetic alteration, of which 22 patients (3.65%) had two genetic alterations and two patients had more than two genetic alterations. Additionally, 50 patients were identified with one or more KRAS mutations (8.29%), 45 patients with EGFR mutations (7.46%), and 1.82% with PIK3CA mutations and 0.66% with BRAF mutations. Furthermore, 50% of the co-occurring alterations were either on KRAS and PIK3CA genes (3/6), on KRAS and BRAF genes (2/6, 33.33%) or on EGFR and PIK3CA genes (1/6, 16.67%), and 10.45% of the patients exhibited PD-L1 overexpression, 5.31% ALK rearrangements, and 2.36% HER2/NEU expression, with no ROS-1 rearrangements detected. Conclusions: Comprehensive testing for somatic alterations in EGFR, BRAF, KRAS, and PIK3CA is significant in guiding therapeutic decisions in lung cancer management. Such testing should be routinely conducted to establish a thorough genetic profile of lung cancers in a manner that is both time-efficient and cost-effective.

Subjects

lung cancer

BRAF

KRAS

EGFR

gene alterations

File(s)

Name

genes-16-01177-v3.pdf

Size

586.26 KB

Format

Adobe PDF

Checksum

(MD5):1005333e4f91477285cf31ed18f56627